Medicinal Cannabis Matters: Friday Roundup - 6 November 2026

The Future of Cannabinoid Medicine

The Cannabis Health Symposium recently brought together healthcare professionals, researchers and industry representatives in Frankfurt to discuss the evidence behind cannabinoid medicines and the challenges surrounding access to treatment.

Discussions covered the need for stronger clinical research and more consistent product standards. Speakers also explored the potential role of cannabinoid medicines in chronic pain management and women’s health. A key message was that progress depends on more than simply gathering evidence. Research findings need to inform prescribing decisions, while appropriate regulation helps ensure patients receive safe and consistent care.

The Evidence on Medicinal Cannabis for Endometriosis

Endometriosis affects an estimated one in ten women of reproductive age worldwide and can cause significant pain, fatigue and disruption to everyday life. With many patients continuing to experience symptoms despite existing treatments, researchers are exploring whether medicinal cannabis could have a role in managing the condition.

Some observational studies and patient surveys have reported improvements in pain, sleep and quality of life among people using medicinal cannabis. The article also highlights the importance of distinguishing symptom management from treating the underlying condition.

Further research, including larger randomised controlled trials, is needed to understand which patients might benefit and which formulations may be appropriate. Anyone considering medicinal cannabis should discuss their options with a qualified prescribing doctor as part of their care plan.

Eight Years of Medicinal Cannabis in the UK

November marks eight years since changes to UK law allowed specialist doctors to prescribe medicinal cannabis in certain circumstances.

But, as a new article from Leafie examines the growing body of research, including findings from the UK Medical Cannabis Registry, which has collected patient-reported outcomes from thousands of people receiving treatment. This type of real-world evidence can help researchers understand how patients respond over time and highlight areas that need further investigation.

Randomised controlled trials remain important for establishing effectiveness, and existing studies have not yet provided clear answers for every condition. The article also discusses barriers to conducting further research, including funding and stigma. Its central argument is that independent, well-designed trials are needed to build on existing findings and help inform future clinical guidance.

For patients, continued research matters because better evidence can help clinicians make informed decisions about treatment suitability. It can also support more consistent guidance and help clarify where medicinal cannabis may have a place in care.

At Medicann, we believe patients deserve clear information and specialist guidance throughout their treatment journey. If you would like to explore whether medicinal cannabis may be suitable for you, our online eligibility checker is a straightforward first step and takes around two minutes to complete.

Disclaimer: This blog post and the following featured articles are for information only and any articles on external platforms may be amended at any time. Articles that we refer to in our weekly roundup do not reflect the views of Medicann.